DENDRID
LOE ApproachingNDAOPHTHALMICSOLUTION/DROPS
Approved
Jun 1963
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
DENDRID is an ophthalmic solution (eye drops) approved in 1963 as a small-molecule NDA by Alcon. The specific mechanism of action and indications are not publicly detailed in available data, but the formulation targets ocular conditions requiring topical administration.
LOE Approaching
As a 60-year-old product entering LOE, commercial teams face portfolio transition and reduced headcount allocation toward brand maintenance rather than growth.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
DENDRID currently shows zero linked job openings, reflecting its mature LOE status and limited growth potential. Career mobility on this product is constrained; roles focus on legacy brand management and commercial wind-down rather than advancement opportunities.
Brand ManagerField Sales Representative
Worked on DENDRID at Alcon? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.